| Synonyms |
Plerixafor D4; 1,1'-[(2H4)-1,4-Phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane) |
| IUPAC Name |
1-[[2,3,5,6-tetradeuterio-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane |
| Molecular Weight |
506.81 |
| Molecular Formula |
C28H50D4N8 |
| Canonical SMILES |
C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3 |
| InChI |
InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2/i5D,6D,7D,8D |
| InChIKey |
YIQPUIGJQJDJOS-KDWZCNHSSA-N |
| Boiling Point |
657.5±55.0 °C at 760 mmHg |
| Melting Point |
127-129°C |
| Purity |
95% by HPLC; 95% atom D |
| Density |
1.0±0.1 g/cm3 |
| Solubility |
Soluble in DMSO, Methanol, Water |
| Appearance |
White to Off-white Solid |
| Storage |
Store at -20°C, under inert atmosphere |
| Animal Admin |
Male C57bl/6 mice (6-7 weeks old, weighing 20 g) are used. The animals are acclimated to the housing environment, which is SPF and had a temperature of 22°C and a 12h/12h light/dark cycle for a week. Then, they are randomly divided into following experimental groups, with 8 mice in each group: normal (no specific intervention), UUO+AMD3100 (mice received UUO surgery and 2 mg/kg AMD3100), and UUO+PBS (mice received UUO surgery and the same volume of PBS). AMD3100 and PBS are administered via intraperitoneal injection every day until sacrifice. |
| Complexity |
456 |
| Exact Mass |
506.47225074 |
| In Vitro |
The CXCR4 inhibitor Plerixafor (AMD3100) is a potent inhibitor of CXCL12-mediated chemotaxis (IC50, 5.7 nM) with a potency slightly better than its affinity for CXCR4. Treating the cells with CCX771 or CXCL11 has no effect on CXCL12-mediated MOLT-4 or U937 TEM. In contrast, 10 μM Plerixafor inhibits CXCL12-mediated TEM in both cells lines. Plerixafor (10 μM)-treated cells show a moderate reduction in cell proliferation compared to CXCL12-stimulated cells, which do not reach statistical significance. |
| In Vivo |
Plerixafor (2 mg/kg) administration to UUO mice exacerbates renal interstitial T cell infiltration, resulting in increased production of the pro-inflammatory cytokines IL-6 and IFN-γ and decreased expression of the anti-inflammatory cytokine IL-10. Both perivascular and interstitial fibrosis are significantly reduced by the CXCR4 antagonist, Plerixafor (AMD3100) at 8 weeks. LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg. |
| PSA |
78.66000 |
| Target |
CXCR; HIV |
| XLogP3-AA |
0 |
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1246819-87-3.gif)
